EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD

Eva Katharina Messer iD, Janett Fischer, Toni Herta, Albrecht Boehlig, Madlen Matz-Soja, Adrienn Tuennemann-Tarr, Susanne Gaul, Ulrich Laufs, Thomas Berg

PLOS One · 2026

DOI: 10.1371/journal.pone.0349666 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Eva Katharina Messer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a systemic disorder closely linked to cardiometabolic risk and dysregulated lipid metabolism. Apolipoprotein C3 (ApoC3), a key regulator of triglyceride-rich lipoproteins and mediator of cardiovascular disease, has been implicated in hepatic steatosis. However, its stage-specific role across the MASLD spectrum remains incompletely defined.

Methods

In this cohort study, serum ApoC3 concentrations were quantified in 197 patients with MASLD across different disease stages (non-fibrotic MASLD, fibrosis, cirrhosis, and cirrhosis with hepatocellular carcinoma (HCC)) and compared with 204 blood donor controls. Associations with metabolic parameters, non-invasive fibrosis markers, histology, cardiometabolic comorbidities, and genetic risk variants were analyzed.

Results

ApoC3 levels exhibited a stage-dependent pattern, with significantly lower concentrations in cirrhotic MASLD and HCC compared to non-fibrotic MASLD and controls (median 18.7 vs. 26.6 vs. 27.4 mg/dL, p < 0.05). Lower ApoC3 levels were associated with markers of advanced liver disease, including higher bilirubin, liver stiffness, Fibrosis-4 index, and NAFLD fibrosis score. In contrast, higher ApoC3 levels were observed in early-stage MASLD and were associated with cardiometabolic comorbidities and dyslipidemia. ApoC3 correlated positively with triglycerides (r = 0.485, p < 0.001) and controlled attenuation parameter values (r = 0.274, p = 0.004), and was highest in patients with severe steatosis (S3) and increased inflammatory activity (NAS ≥ 5). Diagnostic performance for cirrhosis was modest (AUC 0.642) and for HCC 0.673.

Conclusion

ApoC3 demonstrates a biphasic, stage-dependent profile in MASLD, with elevated levels reflecting hepatic steatosis, and metabolic dysfunction in early disease, and declining levels likely indicating impaired hepatic function in advanced stages. These findings position ApoC3 as a link between hepatic lipid accumulation and cardiovascular risk rather than a linear marker of disease severity. Its clinical utility may lie in integrative, multi-parameter models rather than as a standalone biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein C-IIIFatty LiverNon-alcoholic Fatty Liver DiseaseHumansFemaleMaleMiddle AgedCarcinoma, HepatocellularLiver CirrhosisBiomarkersLiver NeoplasmsAgedCohort Studies

Substanzen

Apolipoprotein C-IIIAPOC3 protein, humanBiomarkers

Autor:innen und Institutionen

  • Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
  • Department of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany.
  • Berlin Institute of Health at Charité-Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program, Berlin, Germany.
  • Clinic for Internal Medicine, Community Hospital Delitzsch, Delitzsch, Germany.
  • Clinic of Cardiology, Department of Medicine IV, Leipzig University Medical Center, Leipzig, Germany.
  • LeiCeM - Leipzig Center of Metabolism, Leipzig University, Leipzig, Germany.

ORCID-Profile: Eva Katharina Messer

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Messer, E. K., Fischer, J., Herta, T., Boehlig, A., Matz-Soja, M., Tuennemann-Tarr, A., Gaul, S., Laufs, U., & Berg, T. (2026). Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD. PLOS One. https://doi.org/10.1371/journal.pone.0349666

Vancouver

Messer EK, Fischer J, Herta T, Boehlig A, Matz-Soja M, Tuennemann-Tarr A, et al. Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD. PLOS One. 2026. doi:10.1371/journal.pone.0349666

BibTeX
@article{Messer2026,
  author = {Messer, Eva Katharina and Fischer, Janett and Herta, Toni and Boehlig, Albrecht and Matz-Soja, Madlen and Tuennemann-Tarr, Adrienn and Gaul, Susanne and Laufs, Ulrich and Berg, Thomas},
  title = {Stage-dependent dynamics of Apolipoprotein C3 across the spectrum of MASLD},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0349666}
}
Kostenlos starten →